NeuroSense Therapeutics
met primary exploratory positive clinical signal observed phase a trial with | NeuroSense Therapeutics
Company
Deck Type
Sector
Industry
Deck date
June 2023
Slide
18 of 34
Similar slides by NeuroSense Therapeutics
See diffirences between slides (animation)
Investor Presentation
January 2024
met primary and exploratory in phase a study | NeuroSense Therapeutics
Investor Presentation
December 2023
met primary and exploratory in phase a study | NeuroSense Therapeutics
Related slides by other companies
Oculis
Investor Presentation
July 2023
in acute optic neuritis phase acuity trial acuity acute optic neuritis with a origin | Oculis
MAIA Biotechnology
Investor Presentation
October 2023
agreement announces clinical supply with for phase clinical trial evaluating thio in sequential administration with in advanced non small cell lung cancer | MAIA Biotechnology
Sema4
SPAC
August 2021
improving efficiency and outcomes in drug development | Sema4
Dare Bioscience
Investor Presentation
July 2023
exploratory phase respond study agenda | Dare Bioscience
Other recent decks by NeuroSense Therapeutics
See all presentations (3 decks)
Investor Presentation
January 2024
Investor Presentation
December 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io